An investigation was conducted to evaluate the effectiveness of cycloplegics to the treatment of myopia. A total of 247 school myopia patients were admitted to this study and were randomly devided to three groups: group 1, 1% atropine eyedrop every other night; group 2, 1% cyclogyl eyedrop every night and group 3, 0.9% NaC1 eyedrop every night. Upon the end of one year, there were l0 patients having received the medications continuously for more than 8 months, 36 in atropine group, 32 in cyclogyl group and 35 in NaC1 group. These 103 patients were compiled in the present evaluation. The mean progression of myopia per month was 0.016 diopter for atropine group, 0.042 diopter for cyclogyl group and 0.073 diopter for NaCl group. The differences were statistically significant between atropine and NaC1 groups, cyclogyl and NaCl groups, and atropine and cyclogyl groups. It has been found that atropine and cyclogyl are effective in slowing down the progression of myopia although can not completely arrest its progression. Due to the possible side effect of atropine, the authors suggest short acting cycloplegics (cyclogyl) as the first line medication for arresting myopic progression. If it failed, atropine can then be used.
An investigation was conducted to evaluate the effectiveness of cycloplegics to the treatment of myopia. A total of 247 school myopia patients were admitted to this study and were randomly devided to three groups: group 1, 1% atropine eyedrop every other night; group 2, 1% cyclogyl eyedrop every night and group 3, 0.9% NaC1 eyedrop every night. Upon the end of one year, there were l0 patients having received the medications continuously for more than 8 months, 36 in atropine group, 32 in cyclogyl group and 35 in NaC1 group. These 103 patients were compiled in the present evaluation. The mean progression of myopia per month was 0.016 diopter for atropine group, 0.042 diopter for cyclogyl group and 0.073 diopter for NaCl group. The differences were statistically significant between atropine and NaC1 groups, cyclogyl and NaCl groups, and atropine and cyclogyl groups. It has been found that atropine and cyclogyl are effective in slowing down the progression of myopia although can not completely arrest its progression. Due to the possible side effect of atropine, the authors suggest short acting cycloplegics (cyclogyl) as the first line medication for arresting myopic progression. If it failed, atropine can then be used.